PR Newswire Clinical TrialsOriginal article
Nanoscope Therapeutics Announces U.S. Food and Drug Administration Acceptance of Biologics License Application for MOGENRY for the Treatment of Retinitis Pigmentosa with Severe Vision Loss
BLA FilingMOGENRYPositive
AI Analysis
Summary
Nanoscope Therapeutics announced FDA acceptance of a Biologics License Application for MOGENRY, a potential first-in-class gene-agnostic treatment for retinitis pigmentosa with severe vision loss, supported by positive Phase 2b/3 RESTORE trial and long-term REMAIN follow-up data.
Clinical Trial Data
Phase
2b/3
Primary Endpoint
Met
Outcome Details
FDA acceptance of Biologics License Application
Importance:7/10
Sentiment:
0.80
BLA_AcceptanceGene_TherapyRetinitis_PigmentosaFDA_RegulatoryPhase_2b/3_Data
Related Companies
Read the original article
Published by PR Newswire Clinical Trials on September 9, 2026 11:03 AM